We help companies with a wide variety of due diligence challenges, using the depth of our in-house expertise. Projects range from assessing the quality of the clinical trials in an in-licensing deal to providing risk advice to companies providing clinical trial insurance.
Independent assessment of data
Advance notice of regulatory risks
Insight of investment risk
Recent examples of our work:
Due diligence on behalf of a client in the process of acquiring a leading CRO
Determining the status of compliance with GxP regulations, allowed a client to progress with an acquisition.
Assessed clinical trial data quality prior to in-licensing deal
One of the many strategic options that pharmaceutical companies are adopting is to fill their R&D pipeline with in-licensed compounds from other companies.
Part of the process of in-licensing compounds is to manage the inherent risk. Increasingly, companies that in-license compounds that are under clinical development want to manage the risk by understanding more fully the clinical programme. Are the current programmes robust? Will any of the programmes need to be repeated?
ADAMAS has the team, the experience, the skills and the competencies to conduct independent due diligence of a clinical development programme to help companies understand and manage the associated risk.
Thank you once again for your assistance and quick turn around on the report. The audit was quite thorough (as usual) and I know your findings opened some eyes here. I very much appreciate your professionalism and how you conduct the post audit TCs. Thanks again!
If you've got any questions or queries about our services, careers, or training, please get in touch.
We have 500+ years combined experience, working around the globe there isn’t anything we’ve not encountered in our sector. We're very approachable and happy to help.